Compare CWK & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWK | WGS |
|---|---|---|
| Founded | 1784 | 2017 |
| Country | United States | United States |
| Employees | 53000 | N/A |
| Industry | Real Estate | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2018 | 2020 |
| Metric | CWK | WGS |
|---|---|---|
| Price | $11.86 | $86.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $17.64 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 1.6M | 635.6K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $10,288,200,000.00 | $427,539,000.00 |
| Revenue This Year | $6.87 | $29.98 |
| Revenue Next Year | $5.98 | $25.92 |
| P/E Ratio | $71.68 | ★ N/A |
| Revenue Growth | 8.91 | ★ 39.97 |
| 52 Week Low | $11.57 | $32.21 |
| 52 Week High | $17.40 | $170.87 |
| Indicator | CWK | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 48.88 |
| Support Level | $11.84 | $79.97 |
| Resistance Level | $14.21 | $94.82 |
| Average True Range (ATR) | 0.45 | 6.18 |
| MACD | -0.07 | -1.39 |
| Stochastic Oscillator | 16.67 | 20.53 |
Cushman & Wakefield is a global commercial real estate services firm providing leasing, capital markets, property management, and project management to occupiers, owners, and investors across property types including office, industrial, retail, and data centers. The firm traces its roots back to 1917, when it was founded by brothers-in-law J. Clydesdale Cushman and Bernard Wakefield, and grew into its current form largely through a transformative 2015 merger with DTZ, a firm backed by TPG, PAG Asia Capital, and Ontario Teachers' Pension Plan. As of early 2026, the firm operates across roughly 400 offices in 60 countries with approximately 53,000 people.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.